Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102. Results from the randomized, double-blind, placebo-controlled ...

In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the pump and dump stocks. Pump and dump stocks are typically characterized by high 52-week ...

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, Marketbeat reports.

Tonight will be dry and largely clear, with just a few patches of cloud developing. There will be a moderate to fresh easterly breeze. Sunday Tomorrow will bring a dry and fine day with plenty of ...

You only have one brain and so it’s important to buy the best motorbike helmet you can afford. That doesn’t always mean spending £1000+ on a race-ready carbon lid, though, and there are ...

Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

But does it offer enough to entice users of the older and still mighty adequate MacBook Pro laptops with the M1 Pro and M1 Max chips? After all, there's a lot more going on with the Pro models than ...

Shares of Arvinas ARVN plummeted 52.7% on Tuesday after the company and partner, Pfizer PFE, announced mixed results from a late-stage breast cancer study of its lead candidate, vepdegestrant.